Industry News

Mast Therapeutics, Inc. today announced that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into a collaborative agreement with Philips Respironics, Inc., the sleep and respiratory care business of Royal Philips related to the supply of Philips' I-neb ® Adaptive Aersol Delivery devices and related consumables for the nebulized delivery of the Company's lead product candidate, AIR001, a sodium nitrite solution for..."/>
Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001
Synergy Pharmaceuticals Inc. today presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the U.S. Food and Drug Administration for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. These data, which were presented at the American College of Gastroenterology annual scientific meeting, showed that plecanatide was associated with low..."/>
Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Teladoc, Inc., the first and largest telehealth platform in the United States, announced that Alan Roga, MD, FACEP, Teladoc senior vice president and general manager, provider market, will participate in the J.P. Morgan Healthcare Banking Group’ s 4th Annual Healthcare Advisory Council."/>
Teladoc Senior Vice President Dr. Alan Roga to Address Hospital and Health System Chief Financial Officers at J.P. Morgan Healthcare Advisory Council
Invacare Corporation announces that it will release its financial results for the third quarter 2016 before the market opens on Monday, October 31, 2016. The company will provide a live conference call and webcast to review its third quarter financial results on Monday, October 31, 2016 at 8:30 AM ET. Investors and other interested parties may access the conference call in the following ways:."/>
Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results
Moleculin Biotech, Inc.,, a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it will host a conference call to discuss important positive developments regarding Annamycin, its drug candidate for the treatment of Acute Myeloid Leukemia, as well..."/>
Moleculin Announces Conference Call to Discuss Positive Developments Regarding Annamycin
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that Samuel R. Chapin has been elected to the Company’ s Board of Directors. "I am pleased to welcome Samuel to our Board, as he brings extensive experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions, along with deep knowledge of the industrial marketplace,” said Robert Friel, Chairman and Chief Executive Officer,..."/>
PerkinElmer Elects Samuel Chapin to Board of Directors
Extendicare Inc. announced that it has declared a cash dividend of C $0.04 per common share of the Company for the month of October 2016, which is payable on November 15, 2016 to shareholders of record at the close of business on October 31, 2016. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act. Extendicare has a Dividend Reinvestment Plan, which provides Canadian resident holders of Common Shares with the..."/>
Extendicare Announces October 2016 Dividend of C$0.04 per Share
ConforMIS, Inc., a medical technology company that develops, manufactures and sells joint replacement implants that are customized to fit each patient's unique anatomy, today announced that The Journal of Arthroplasty has accepted for printed publication, and published online, the results of an in vivo clinical study comparing the motion patterns of patients with a ConforMIS iTotal ® CR implant versus patients with a traditional off-the-shelf..."/>
ConforMIS Announces Publication of Clinical Study Demonstrating iTotal CR Customized Implants Better Approximate Normal Knee Motion When Compared to a Leading Off-the-Shelf Total Knee Implant
Allergan plc, a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, today announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending..."/>
Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae
Dextera Surgical Inc., manufacturer of the smallest-profile and most maneuverable articulating surgical stapler platform on the market for minimally invasive surgery, today announced the company has entered into a marketing and distribution agreement with B. Braun Surgical S.A. to bring Dextera’ s MicroCutter 5/ 80 surgical stapler to surgeons in Spain. B. Braun Surgical S.A. is the distribution arm of the B. Braun Aesculap Group headquartered in..."/>
Dextera Surgical Signs Agreement with B. Braun Surgical S.A. for MicroCutter Distribution in Spain
Lipocine Inc., a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and Drug Administration regarding its New Drug Application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. The purpose of the meeting was to review the..."/>
Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome. NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels and low blood glucose..."/>
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
PTC Therapeutics, Inc. today provided a regulatory update on Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC Therapeutics announced today that at the end of last week, the Office of Drug Evaluation I of the U.S. Food and Drug Administration denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products on February 22, 2016 regarding PTC's New..."/>
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at..."/>
Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG
Profound Medical Corp. announced today that it has entered into an agreement with a syndicate of underwriters led by GMP Securities L.P., pursuant to which the Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, 15,820,000 common shares of the..."/>
Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
Five Star Quality Care by ABP Acquisition, an entity controlled by Barry M. Portnoy and Adam D. Portnoy, the company said. Senior Star announced that it intends to commence a tender offer through an affiliated entity for up to 10 million shares of the company's common stock in the coming days at a price of USD3.45 per share in cash and urges FVE..."/>
Senior Star to offer USD3.45 per share for Five Star Quality Care stock
Rayonier Advanced Materials Inc., LSB Industries Inc., Chemical& Mining Company of Chile Inc., and ChromaDex Corporation. On Friday, the NASDAQ Composite ended the trading session at 5,214.16, up 0.02%; the Dow Jones..."/>
How These Chemicals Stocks are Faring? -- Rayonier Advanced Materials, LSB Industries, Chemical & Mining Co. of Chile, and ChromaDex
Nuvo Pharmaceuticals Inc.,, a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has received approval from the German Federal Institute for Drugs and Medical Devices and Ethical Review Committee to conduct a placebo controlled Phase 3 trial of Pennsaid 2% for the treatment of acute ankle sprains. The 130 patient Trial will..."/>
Nuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
Nuvo Pharmaceuticals Inc.,, a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced it has received approval from the German Federal Institute for Drugs and Medical Devices and Ethical Review Committee to conduct a placebo controlled Phase 3 trial of Pennsaid 2% for the treatment of acute ankle sprains."/>
Nuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:. Date: Tuesday, October 18, 2016 Time: 3:30 PM Eastern Time Location: Westin St. Francis Hotel in San Francisco, CA Main Therapeutic Focus: Immunology Webcast:"/>
Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
Editas Medicine, Inc., a leading genome editing company, today announced that its scientists will present data on the use of CRISPR/Cas9-mediated gene editing in human hematopoietic stem/progenitor cells in a poster presentation at the 24 th Annual Congress of the European Society of Gene and Cell Therapy, hosted in conjunction with the 2016 International Symposia of the International Society for Stem Cell Research. The meeting will take place..."/>
Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016
Pacific Biosciences of California, Inc., today announced that its Single Molecule, Real-Time Sequencing technology will be featured in more than 38 presentations at this week’ s American Society of Human Genetics annual meeting taking place in Vancouver,..."/>
Novel Human Genetics Discoveries Using PacBio Long-Read Sequencing to be Presented at ASHG Annual Meeting

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology637 Articles
Consumer Discretionary599 Articles
Financials564 Articles
Health Care407 Articles
Industrials390 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at